NASDAQ: AKYAAkoya Biosciences Inc Stock
$1.49+0.04 (+2.76%)
Updated Mar 27, 2025
AKYA Price
$1.49
Fair Value Price
N/A
Market Cap
$74.23M
52 Week Low
$1.39
52 Week High
$4.69
P/E
-1.33x
P/B
9.77x
P/S
1.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$81.67M
Earnings
-$55.37M
Gross Margin
58.6%
Operating Margin
-54.84%
Profit Margin
-67.8%
Debt to Equity
15.46
Operating Cash Flow
-$44M
Beta
1.47
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AKYA Overview
Akoya Biosciences, Inc. provides spatial biology solutions focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, which helps to understand disease progression and patient responses to therapy. Its flagship products include PhenoCycler, PhenoImager, and PhenoImager HT. The company was incorporated in 2015 and is headquartered in Marlborough, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKYA's potential to beat the market
- AKYA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
AKYA
RankedUnranked of 43
RankedUnranked of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $49.98 | B | |
| $103.27 | B | |
| $6.06 | B |
Be the first to know about important AKYA news, forecast changes, insider trades & much more!
AKYA News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKYA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKYA is poor value based on its book value relative to its share price (9.77x), compared to the US Medical Instruments & Supplies industry average (3.8x)
P/B vs Industry Valuation
AKYA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AKYA due diligence checks available for Premium users.
Valuation
AKYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.33x
Industry
42.1x
Market
31.08x
AKYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.77x
Industry
3.8x
AKYA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKYA's financial health
Profit margin
Revenue
$21.3M
Net Income
-$8.2M
Profit Margin
-38.4%
AKYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AKYA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$125.0M
Liabilities
$117.4M
Debt to equity
15.46
AKYA's short-term assets ($76.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKYA's long-term liabilities ($87.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKYA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$2.7M
Financing
-$486.0k
AKYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKYA vs Medical Stocks
Akoya Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.